NYSEHealth CareBiological Products, (No Diagnostic Substances)DURHAM, NC

Pelthos Therapeutics Inc. PTHS

Ask your AI

Estimated market cap $29.24M3.93M shares, shares as of Nov 5, 2026CIK 1919246

Insider trades, 12 mo

2 buys · 21 sells

$441.4K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

21.9% of shares · 8 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Pelthos Therapeutics Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Pelthos Therapeutics Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

23 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jul 2, 2026. Insiders have two business days to file.

Recent insider trades

Ezra M. Friedberg Director	Jul 2 Form 4 ↗	Sale 10b5-1 plan	−$656 24 sh @ $27.33	-72.4%
Ezra M. Friedberg Director	Jul 2 Form 4 ↗	Sale 10b5-1 plan	−$13.9K 534 sh @ $26.03	-72.4%
Matthew Pauls Director	Jul 2 Form 4 ↗	Sale 10b5-1 plan	−$2,572 94 sh @ $27.36	-72.4%
Matthew Pauls Director	Jul 2 Form 4 ↗	Sale 10b5-1 plan	−$18.0K 692 sh @ $26.00	-72.4%
Peter Greenleaf Director	Jul 2 Form 4 ↗	Sale 10b5-1 plan	−$2,318 85 sh @ $27.27	-72.4%

All PTHS insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

860,453 shares

18 funds report PTHS. Values checked against market prices.

Funds own 36% of shares (Q2 2026)

24 funds hold the stock.

Q3 2026: 22% · 5,560 of ~8,900 funds reported so far

Q3 202515%
Q4 202529%
Q1 202627%
Q2 202636%
Q3 2026 (so far)22%

Q3 2026. 4 new, 8 added to, 5 trimmed, 10 exited since Q2 2026.

Top 13F holders
#
1	Murchinson Ltd. 13F ↗	311,019	$6.5M	+2.2%
2	AIGH Capital Management LLC 13F ↗	256,012	$5.4M	-22.2%
3	Vanguard Capital Management LLC 13F ↗	95,316	$2.0M	-1.9%
4	Wexford Capital LP 13F ↗	84,616	$1.8M	+278.4%
5	Persistent Asset Partners Ltd 13F ↗	20,228	$425.0K	+236.7%
6	Knott David M Jr 13F ↗	17,644	$370.7K	-20.1%
7	Geode Capital Management, LLC 13F ↗	16,575	$348.2K	+13.1%
8	1492 Capital Management LLC 13F ↗	14,577	$306.3K	+40.4%
9	Pale Fire Capital SE 13F ↗	12,919	$271.4K	unchanged
10	State Street Corp 13F ↗	10,800	$226.9K	+10.2%

Download CSV Every fund that holds PTHS, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Pelthos Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Pelthos Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2025	14	—	462,763	$13.0M
Q4 2025	15	+1	899,359	$27.9M
Q1 2026	17	+2	912,311	$19.2M
Q2 2026	24	+7	1.36M	$38.5M
Q3 2026	18	-6	860,453	$18.1M

Each point is a quarter-end, from Q3 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (171126204). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes6 in 12 mo 8-K events3 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 1 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Pending deal1 deal filed lately IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Pelthos Therapeutics Inc.
Address: 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC 27703
Phone: 919-908-2422
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: NV
Listed as: PTHS (NYSE)
Former names: Channel Therapeutics Corp (until 2025); Chromocell Therapeutics Corp (until 2024)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$7.44−$0.59 (−7.35%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $7.44 · High $20.50Nov 13, 2026

Aug 13, 2026Low $7.44 · High $28.95Nov 13, 2026

Nov 13, 2025Low $7.44 · High $34.68Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.